Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.

被引：0
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Christensen, LL [1 ]
Sanchez, EQ [1 ]
Molmenti, EM [1 ]
Gonwa, TA [1 ]
Goldstein, RM [1 ]
Levy, MF [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1869
引用
收藏
页码：639A / 639A
页数：1
相关论文
共 50 条
  • [1] Natural history of recurrence of hepatitis C (HEP CR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS).
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    [J]. HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [2] Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients?
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Molmenti, EP
    Klintmalm, GB
    [J]. TRANSPLANTATION, 2000, 69 (08) : S120 - S120
  • [3] Initial clinical evidence that mofetil mycophenolate (MMF) antiviral effects may delay the recurrence of hepatitis C (HEP C) and reduce the incidence of CMB infection in HEP C liver transplant recipients (OLT).
    Fasola, CG
    Netto, G
    Jennings, LW
    Jung, GJ
    Marubashi, S
    Sanchez, EQ
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Klintmalm, GB
    [J]. HEPATOLOGY, 2000, 32 (04) : 290A - 290A
  • [4] Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1563 - 1564
  • [5] Conversion to mycophenolate mofetil (MMF) in pediatric kidney transplant recipients.
    Machado, PGP
    Nogueira, PCK
    Park, SI
    Tedesco-Silva, H
    Pestana, JOM
    [J]. PEDIATRIC TRANSPLANTATION, 2005, 9 : 92 - 92
  • [6] Mycophenolate mofetil (MMF) in pediatric liver transplant recipients
    Dhawan, A
    Lewis, PN
    Heaton, ND
    Baker, AJ
    Rela, M
    Hadzic, N
    Srinivasan, P
    MieliVergani, G
    [J]. HEPATOLOGY, 1997, 26 (04) : 1487 - 1487
  • [7] Mycophenolate mofetil reduces rejection rates in hepatitis C positive liver transplant recipients.
    Baillie, GM
    Taber, DJ
    Rogers, J
    Lin, A
    Baliga, P
    Chavin, KD
    [J]. HEPATOLOGY, 2002, 36 (04) : 655A - 655A
  • [8] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [9] Mycophenolate mofetil (MMF) therapy for chronic rejection in renal transplant (RTX) recipients.
    Glicklich, D
    Schurter, G
    Greenstein, S
    Mallis, M
    Clemetson, S
    Tellis, V
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3181 - A3181
  • [10] Hepatitis C recurrence (HCVR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS): A long-term follow up
    Fasola, CG
    Netto, GJ
    Sanchez, EQ
    Chinnakotla, S
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 356 - 356
12345